Agnė Žiniauskaitė1, Symantas Ragauskas1, Anita K Ghosh2, Rubina Thapa1, Anne E Roessler3, Peter Koulen4, Giedrius Kalesnykas1, Jenni J Hakkarainen1, Simon Kaja5. 1. Experimentica Ltd., Kuopio, Finland. 2. Graduate Program in Neuroscience, Health Sciences Division, Loyola University Chicago, Maywood, IL, USA; Departments of Ophthalmology and Molecular Pharmacology & Therapeutics, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA. 3. K&P Scientific LLC, Oak Park, IL, USA. 4. Vision Research Center, Departments of Ophthalmology and Biomedical Sciences, School of Medicine, University of Missouri - Kansas City, Kansas City, MO, USA. 5. Experimentica Ltd., Kuopio, Finland; Graduate Program in Neuroscience, Health Sciences Division, Loyola University Chicago, Maywood, IL, USA; Departments of Ophthalmology and Molecular Pharmacology & Therapeutics, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA; K&P Scientific LLC, Oak Park, IL, USA. Electronic address: skaja@luc.edu.
Abstract
PURPOSE: To determine the efficacy of the superoxide dismutase mimetic, manganese(III) tetrakis(1-methyl-4-pyridyl) porphyrin (Mn-TM-2-PyP), in vitro in human corneal epithelial (HCE-T) cells and in vivo in a preclinical mouse model for dry-eye disease (DED). METHODS: In vitro, HCE-T cultures were exposed either to tert-butylhydroperoxide (tBHP) to generate oxidative stress or to hyperosmolar conditions modeling cellular stress during DED. Cells were pre-treated with Mn-TM-2-PyP or vehicle. Mn-TM-2-PyP permeability across stratified HCE-T cells was assayed. In vivo, Mn-TM-2-PyP (0.1% w/v in saline) was delivered topically as eye drops in a desiccating stress/scopolamine model for DED. Preclinical efficacy was compared to untreated, vehicle- and ophthalmic cyclosporine emulsion-treated mice. RESULTS: Mn-TM-2-PyP protected HCE-T cells in a dose-dependent manner against tBHP-induced oxidative stress as determined by calculating the IC50 for tBHP in the resazurin, MTT and lactate dehydrogenase release cell viability assays. Mn-TM-2-PyP did not protect HCE-T cells from hyperosmolar insult. Its permeability coefficient across a barrier of HCE-T cells was 1.1 ± 0.05 × 10-6 cm/s and the mass balance was 62 ± 0.6%. In vivo, topical dosing with Mn-TM-2-PyP resulted in a statistically significant reduction of corneal fluorescein staining, similar to ophthalmic cyclosporine emulsion. Furthermore, Mn-TM-2-PyP significantly reduced leukocyte infiltration into lacrimal glands and prevented degeneration of parenchymal tissue. No protective effect against loss of conjunctival goblet cells was observed. Notably, Mn-TM-2-PyP did not produce ocular toxicity when administered topically. DISCUSSION: Our data suggest that Mn-TM-2-PyP, a prototypic synthetic metalloporphyrin compound with potent catalytic antioxidant activity, can improve signs of DED in vivo by reducing oxidative stress in corneal epithelial cells. Published by Elsevier Inc.
PURPOSE: To determine the efficacy of the superoxide dismutase mimetic, manganese(III) tetrakis(1-methyl-4-pyridyl) porphyrin (Mn-TM-2-PyP), in vitro in human corneal epithelial (HCE-T) cells and in vivo in a preclinical mouse model for dry-eye disease (DED). METHODS: In vitro, HCE-T cultures were exposed either to tert-butylhydroperoxide (tBHP) to generate oxidative stress or to hyperosmolar conditions modeling cellular stress during DED. Cells were pre-treated with Mn-TM-2-PyP or vehicle. Mn-TM-2-PyP permeability across stratified HCE-T cells was assayed. In vivo, Mn-TM-2-PyP (0.1% w/v in saline) was delivered topically as eye drops in a desiccating stress/scopolamine model for DED. Preclinical efficacy was compared to untreated, vehicle- and ophthalmic cyclosporine emulsion-treated mice. RESULTS:Mn-TM-2-PyP protected HCE-T cells in a dose-dependent manner against tBHP-induced oxidative stress as determined by calculating the IC50 for tBHP in the resazurin, MTT and lactate dehydrogenase release cell viability assays. Mn-TM-2-PyP did not protect HCE-T cells from hyperosmolar insult. Its permeability coefficient across a barrier of HCE-T cells was 1.1 ± 0.05 × 10-6 cm/s and the mass balance was 62 ± 0.6%. In vivo, topical dosing with Mn-TM-2-PyP resulted in a statistically significant reduction of corneal fluorescein staining, similar to ophthalmic cyclosporine emulsion. Furthermore, Mn-TM-2-PyP significantly reduced leukocyte infiltration into lacrimal glands and prevented degeneration of parenchymal tissue. No protective effect against loss of conjunctival goblet cells was observed. Notably, Mn-TM-2-PyP did not produce ocular toxicity when administered topically. DISCUSSION: Our data suggest that Mn-TM-2-PyP, a prototypic synthetic metalloporphyrin compound with potent catalytic antioxidant activity, can improve signs of DED in vivo by reducing oxidative stress in corneal epithelial cells. Published by Elsevier Inc.
Authors: K Araki-Sasaki; Y Ohashi; T Sasabe; K Hayashi; H Watanabe; Y Tano; H Handa Journal: Invest Ophthalmol Vis Sci Date: 1995-03 Impact factor: 4.799
Authors: Won Choi; Cui Lian; Li Ying; Ga Eon Kim; In Cheon You; Soo Hyun Park; Kyung Chul Yoon Journal: Curr Eye Res Date: 2016-01-05 Impact factor: 2.424
Authors: Ruzhi Deng; Xia Hua; Jin Li; Wei Chi; Zongduan Zhang; Fan Lu; Lili Zhang; Stephen C Pflugfelder; De-Quan Li Journal: PLoS One Date: 2015-05-29 Impact factor: 3.240
Authors: Anita Kirti Ghosh; Rubina Thapa; Harsh Nilesh Hariani; Michael Volyanyuk; Sean David Ogle; Karoline Anne Orloff; Samatha Ankireddy; Karen Lai; Agnė Žiniauskaitė; Evan Benjamin Stubbs; Giedrius Kalesnykas; Jenni Johanna Hakkarainen; Kelly Ann Langert; Simon Kaja Journal: Pharmaceutics Date: 2021-08-30 Impact factor: 6.525
Authors: Anita K Ghosh; Vidhya R Rao; Victoria J Wisniewski; Alexandra D Zigrossi; Jamie Floss; Peter Koulen; Evan B Stubbs; Simon Kaja Journal: Antioxidants (Basel) Date: 2020-04-16